[{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Qualigen","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Merger","leadProduct":"Galacto-oligosaccharide","moa":"Lactase enzyme","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ritter Pharmaceuticals \/ Qualigen","highestDevelopmentStatusID":"9","companyTruncated":"Ritter Pharmaceuticals \/ Qualigen"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cytocom","sponsor":"Cleveland BioLabs","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Noroxymorphone analogs","moa":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Cytocom \/ Cleveland BioLabs","highestDevelopmentStatusID":"9","companyTruncated":"Cytocom \/ Cleveland BioLabs"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Cytocom","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Merger","leadProduct":"CYTO-200","moa":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Cytocom \/ Cleveland BioLabs","highestDevelopmentStatusID":"9","companyTruncated":"Cytocom \/ Cleveland BioLabs"},{"orgOrder":0,"company":"MRM Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"MH002","moa":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"MRM Health \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"MRM Health \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23p19 subunit","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Brazikumab","moa":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AbbVie Inc","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ AbbVie Inc"},{"orgOrder":0,"company":"MRM Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2023","type":"Not Applicable","leadProduct":"MH002","moa":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"MRM Health \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"MRM Health \/ Not Applicable"}]

Find Gastroenterology Drugs in Phase II/III Clinical Development

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : AstraZeneca and Allergan have terminated their previous license agreement and all rights to brazikumab have therefore now returned to AstraZeneca.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 11, 2020

                          Lead Product(s) : Brazikumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : AstraZeneca

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          Abbvie CB

                          02

                          Details : AstraZeneca will acquire brazikumab, in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 27, 2020

                          Lead Product(s) : Brazikumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : AstraZeneca

                          Deal Size : Undisclosed

                          Deal Type : Divestment

                          Abbvie CB

                          03

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : HIL-214, an investigational IM vaccine for norovirus-related gastroenteritis, did not meet its primary endpoint in the NEST-IN1 trial. The company will stop its development in infants aged 5 months.

                          Brand Name : HIL-214

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          July 08, 2024

                          Lead Product(s) : HIL-214

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : Tremfya (guselkumab) is a selective IL-23 p19 inhibitor antibody, which is being evaluated for the treatment of moderately to severely active ulcerative colitis.

                          Brand Name : Tremfya

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 23, 2023

                          Lead Product(s) : Guselkumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : MH002 is currently the most advanced rationally-designed consortium therapy, which is investigated for the treatment of mild-to-moderate Ulcerative Colitis.

                          Brand Name : MH002

                          Molecule Type : Undisclosed

                          Upfront Cash : Not Applicable

                          September 19, 2023

                          Lead Product(s) : MH002

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : MEDI2070 (brazikumab) discontinuation of the inflammatory bowel disease development programme, an anti-IL-23 monoclonal antibody, being investigated for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC)

                          Brand Name : MEDI2070

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 01, 2023

                          Lead Product(s) : Brazikumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : AbbVie Inc

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : Validive® (clonidine hydrochloride) is a novel mucobuccal tablet (MBT) formulation of clonidine. The mucobuccal tablet provides for prolonged local delivery of clonidine to the regions of oral mucosal radiation damage in oropharyngeal cancer (OPC) patie...

                          Brand Name : Validive

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 27, 2022

                          Lead Product(s) : Clonidine

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : New data show proportions of patients treated with TREMFYA (guselkumab) who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose groups in the Phase 2 GALAXI 1 study.

                          Brand Name : Tremfya

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 24, 2022

                          Lead Product(s) : Guselkumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable